Discover
SPRO
Spero Therapeutics, Inc.
2.22
2 x 1.63
2 x 2.86
bid
ask
+
0.01
0.45%
2 @ 07:26 AM
2.21 -0.01 (0.45%)
| Ytd | -4.72% | |
| 1y | -23.45% |
2.21
day range
2.27
1.80
52 week range
3.22
| Open | 2.21 | Prev Close | 2.21 | Low | 2.21 | High | 2.27 | Mkt Cap | 128.54M |
| Vol | 381.12K | Avg Vol | 1.01M | EPS | 0.27 | P/E | 8.22 | Forward P/E | -0.83 |
| Beta | 0.63 | Short Ratio | 2.08 | Inst. Own | 23.05% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 2.59 | 200-d Avg | 2.41 | 1yr Est | 5.00 |
| Income Statement | |||
| Total Revenue | 258.00K | ||
| Revenues (USD) | 258.00K | ||
| Gross Profit | 258.00K | ||
| Operating Expenses | 7.80M | ||
| Research and Development Expense | 2.91M | ||
| Selling, General and Administrative Expense | 4.89M | ||
| Operating Income | -7.54M | ||
| Net Income | -7.20M | ||
| Net Income Common Stock | -7.20M | ||
| Net Income Common Stock (USD) | -7.20M | ||
| Consolidated Income | -7.20M | ||
| Earnings per Basic Share | -0.13 | ||
| Earnings per Basic Share (USD) | -0.13 | ||
| Earnings per Diluted Share | -0.13 | ||
| Earning Before Interest & Taxes (EBIT) | -7.20M | ||
| Earning Before Interest & Taxes (USD) | -7.20M | ||
| Weighted Average Shares | 57.28M | ||
| Weighted Average Shares Diluted | 57.28M | ||
| Balance Sheet | |||
| Cash and Equivalents | 56.13M | ||
| Cash and Equivalents (USD) | 56.13M | ||
| Trade and Non-Trade Receivables | 44.00K | ||
| Current Assets | 57.61M | ||
| Property, Plant & Equipment Net | 1.26M | ||
| Total Assets | 59.02M | ||
| Debt Current | 1.97M | ||
| Total Debt | 2.47M | ||
| Current Liabilities | 5.49M | ||
| Debt Non-Current | 507.00K | ||
| Total Liabilities | 6.09M | ||
| Accumulated Retained Earnings (Deficit) | -458.27M | ||
| Shareholders Equity | 52.93M | ||
| Shareholders Equity (USD) | 52.93M | ||
| Assets Non-Current | 1.41M | ||
| Total Debt (USD) | 2.47M | ||
| Liabilities Non-Current | 598.00K | ||
| Trade and Non-Trade Payables | 217.00K | ||
| Tax Liabilities | 163.00K | ||
| Cash Flow | |||
| Net Cash Flow / Change in Cash & Cash Equivalents | 15.86M | ||
| Net Cash Flow from Operations | 15.86M | ||
| Share Based Compensation | 1.11M | ||